Sales of OTC drugs grew above the market pace in the past as well. In 2013, they climbed to 1.78 billion lei (EUR402 million), against RON600 million (EUR150 million) in 2004.
The OTC drug sales increase was driven on the one hand by the population’s rising incomes and on the other hand by companies’ higher promotion budgets. New products were also launched, with most companies being interested in strengthening their foothold on this market.
In this context, the OTC drug market became a battleground for international giants such as Sanofi, Novartis, GSK or Bayer. However, Reckitt Benckiser, including Nurofen in its portfolio, remains the leader of the market.
“OTC drug consumption directly relies on patients’ incomes. In Romania, there’s tight access to drugs because of financial hurdles, still lagging behind many European countries. Other market issues are the RON depreciation, with a direct impact over domestic price increases, and wholesalers’ and pharmacies’ cash shortage,” says Iulia Rosian, Consumer Healthcare Head at Sanofi Romania.
Sanofi includes 25 OTC drugs in its portfolio and this drug category accounts for 25% in the company’s sales in Romania. According to the company, the Consumer HealthCare unit is one of the group’s growth pillars in Romania.
“We can also speak of major opportunities. Owing to educational and prevention campaigns carried out in Romania in recent years, Romanian consumers have grown ever more aware of the importance of prevention,” said Iulia Rosian.
She specified the company’s target is to cement its position and keep a growth pace above the market level by launching new products, through communication campaigns and by breathing new life into brands’ image.
As regards the launch of new products, Sanofi has new projects for 2014 and has already brought MagneVie Express on the market in February.
“We expect the four new products to bring gross sales of around RON5 million this year at consumer prices,” stated Rosian.
She believes the OTC drug segment has a high potential so that 2014 will most likely bring two digit growth, just like in the past years. The company’s most downbeat scenario takes into account an increase of at least 7-8%.
Sanofi announced it would invest around EUR85 million to promote the OTC drugs part of its portfolio.
Cegedim predictions shows the best year for the OTC drug market will be 2017, when growth will near 8% and the weakest one will be 2015, when consumption is set to contract by almost 2%. Taking into account Cegedim forecasts, sales will go beyond RON2.2 billion (EUR490 million) in 2018.
During this period, total drug sales will post an average annual growth rate of 4.8%.
The representatives of GlaxoSmithKline Consumer Healthcare believe the OTC drug segment will see only one-digit growth in the next two-three years on sales on flu drugs.
According to company data, half of the product portfolio of GSK Consumer Healthcare Romania is accounted by OTC drugs. The best-selling OTC drug part of the company’s portfolio is ParaSinus.
On the OTC drug market, the top ten players have overall sales of EUR220 million, half of the overall market. Of domestic producers, only Biofarm and Fiterman Pharma have managed to gain a position among the ten largest companies.
(English version by Catalina Apostoiu)